| Literature DB >> 24764457 |
Yanling Wei1, Wenhua Du2, Xiuqin Xiong2, Xiaoyan He3, Youcai Deng3, Dongfeng Chen4, Xiaohui Li3.
Abstract
BACKGROUND: The epigenetic plasticity hypothesis indicates that pregnancy exposure may result in adult-onset diseases, including hypertension, diabetes and cardiovascular disease, in offspring. In a previous study, we discovered that prenatal exposure to inflammatory stimulants, such as lipopolysaccharides (LPS), could lead to hypertension in adult rat offspring. In the present study, we further demonstrate that maternal inflammation induces cardiac hypertrophy and dysfunction via ectopic over-expression of nuclear transcription factor κB (NF- κB), and pyrrolidine dithiocarbamate (PDTC) can protect cardiac function by reducing maternal inflammation.Entities:
Keywords: Foetal development; Inhibitor of NF-κB; Maternal inflammation; Myocardial remodelling
Year: 2013 PMID: 24764457 PMCID: PMC3874617 DOI: 10.1186/1476-9255-10-35
Source DB: PubMed Journal: J Inflamm (Lond) ISSN: 1476-9255 Impact factor: 4.981
Figure 1Prenatal exposure to LPS influences SBP in rat offspring. Pregnant rats were randomly divided into three groups (n = 8 in each group): control, LPS and LPS + PDTC. SBP in the offspring was measured using the standard tail-cuff method. **P < 0.05 compared with the controls; ##P < 0.05 compared with the offspring of the LPS-treated rats. There was no significant difference between the control group and the LPS + PDTC group (one-way analysis of variance).
Comparison of LV remodelling and function before (4 months) and after (8 months) hypertension
| | ||||||
|---|---|---|---|---|---|---|
| HR (bpm) | 336 ± 12 | 340 ± 27 | 338 ± 36 | 308 ± 5 | 302 ± 7 | 306 ± 9 |
| LVEDD (mm) | 7.47 ± 0.25 | 7.78 ± 0.30 | 7.44 ± 0.28 | 7.83 ± 0.36 | 7.94 ± 0.56 | 7.79 ± 0.35 |
| LVESD (mm) | 4.11 ± 0.22 | 3.81 ± 0.12 | 4.08 ± 0.29 | 4.27 ± 0.30 | 3.78 ± 0.28* | 4.13 ± 0.15# |
| PWT (mm) | 2.02 ± 0.15 | 2.49 ± 0.23* | 1.99 ± 0.11# | 2.42 ± 0.07 | 2.57 ± 0.10* | 2.45 ± 0.27# |
| IVST (mm) | 1.88 ± 0.18 | 1.66 ± 0.27 | 1.81 ± 0.17 | 2.01 ± 0.04 | 2.20 ± 0.10* | 2.02 ± 0.03# |
| Mitral E maximum | | | | | | |
| vel. (mm/s) | 1130 ± 46 | 1267 ± 192 | 1283 ± 303 | 1281 ± 105 | 1305 ± 79 | 1291 ± 124 |
| Mitral A maximum | | | | | | |
| vel. (mm/s) | 691 ± 17 | 693 ± 46 | 671 ± 31 | 908 ± 63 | 572 ± 43* | 916 ± 57# |
| Mitral E/A index | 1.63 ± 0.05 | 1.83 ± 0.23 | 1.93 ± 0.54 | 1.41 ± 0.14 | 2.28 ± 0.15* | 1.41 ± 0.14# |
| Mitral deceleration time (ms) | 48.65 ± 2.97 | 44.67 ± 6.28 | 49.45 ± 4.95 | 42.05 ± 3.80 | 32.12 ± 3.17* | 41.43 ± 2.67# |
| Myocardial performance (Tei) index | 0.35 ± 0.02 | 0.42 ± 0.03 | 0.39 ± 0.01 | 0.34 ± 0.02 | 0.48 ± 0.03* | 0.34 ± 0.02# |
| | | | | | | |
| FS (%) | 45 ± 4.7 | 51 ± 1.6 | 45 ± 5.8 | 45 ± 5.1 | 48 ± 2.0 | 47 ± 4.3 |
| EF (%) | 75 ± 5.2 | 80 ± 4.7 | 74 ± 6.3 | 75 ± 5.4 | 78 ± 1.8 | 77 ± 4.4 |
| | | | | | | |
| Ao end-systolic diameter (mm) | 3.54 ± 0.28 | 3.40 ± 0.66 | 3.56 ± 0.14 | 3.75 ± 0.12 | 3.91 ± 0.13 | 3.80 ± 0.12 |
| Vp (cm/s) | 1322 ± 88.6 | 1233 ± 109.1 | 1354 ± 154.6 | 1160 ± 117.1 | 1040 ± 180.3 | 1146 ± 101.3 |
| VTI (mmHg) | 8.22 ± 0.15 | 8.53 ± 0.32 | 8.35 ± 0.33 | 7.76 ± 0.54 | 7.88 ± 0.68 | 7.64 ± 0.59 |
A summary of the most relevant cardiac measurements that were obtained at 4 and 8 months of age using echocardiography. HR, Heart rate; LV, Left ventricle; LVEDD, LV end-diastolic diameters; LVESD, LV end-systolic diameters; PWT, End-diastolic LV posterior wall thickness; IVST, The thickness of the interventricular septum; Ao, Aorta; vel, velocity; EF, LV ejection fraction; FS, LV fractional shortening; Vp, Ao peak ejection vel.; and VTI, Ao outflow vel./time integral.
The data are presented as the mean ± SEM (n = 6 in each group). *P < 0.05 vs. control group; #P <0.05 vs. LPS group.
Figure 2Effect of prenatal exposure to LPS on the heart/body weight ratio and left ventricle (LV)/total heart weight. The heart/body weight ratio (A) and left ventricle (LV)/total heart weight (B) in the offspring from the LPS or LPS + PDTC groups. **P < 0.05 compared with the controls; ##P <0.05 compared with the offspring of the LPS-treated rats. There was no significant difference between the control group and the LPS + PDTC group (one-way analysis of variance).
Figure 3Effect of prenatal exposure to LPS on cardiac myocyte hypertrophy in adult offspring. (A) Photomicrographs showing the typical myocardial structure in the various groups (hematoxylin-eosin stain; 400×). (B) Quantitative morphometric analysis of the cardiomyocyte area for a single cell. (C) Quantitative morphometric analysis of the cardiomyocyte width for a single cell. **P < 0.05 compared with the controls; ##P <0.05 compared with the offspring of the LPS-treated rats.
Figure 4The pictures (A) show the WB results of activation of the (NF)-κB pathway in offspring from the control, LPS and LPS + PDTC groups. The graphs (B) show the results of the densitometric analysis. Similar results were obtained forix animals in each group. The data are the mean ± SEM. **P < 0.05 compared with the controls; ##P < 0.05 compared with the offspring of the LPS-treated rats.
Figure 5TUNEL analysis in control, LPS and LPS + PDTC groups. (A) Nuclei are shown in blue after staining with DAPI. TUNEL-stained cells show green fluorescence in cells with single-stranded DNA breaks. (B) The apoptotic index analysis of the cardiomyocytes in the heart. **P < 0.05 vs. control group; ##P < 0.05 vs. LPS group.
Figure 6The pictures (A) show the results of WB results on Bcl-2 and Bax. The graphs (B) show the quantitative analysis on the Bcl-2/Bax ratio by western blotting. Lane 1 represents the control tissue, lane 2 represents the LPS-treated tissue, and lane 3 represents the LPS + PDTC-treated tissue. Each value represents the mean ± SEM of six rats. **P < 0.05 vs. control group; ##P < 0.05 vs. LPS group.